Concepedia

Author

Maria Di Bartolomeo

Fondazione IRCCS Istituto Nazionale dei TumoriORCID

Also Known As

DESTINY-CRC01 investigators, Di Bartolomeo, Maria, DiBartolomeo, M., E Bajetta, M Bartolomeo, M DIBARTOLOMEO, M Di Bartolomeo, M. Di Bartolomeo, M. DiBartolomeo, M. Dibartolomeo

560

Publications

15.9K

Citations

61

H-Index

69

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei TumoriUniversity of MilanIstituti di Ricovero e Cura a Carattere ScientificoIstituto Oncologico VenetoAzienda Ospedaliera Universitaria Pisana
MD

About

Maria Di Bartolomeo is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

36

79

7.1K

2

Health Sciences

17

20

1.2K

3

Biostatistics

2

2

55

4

Public Health

1

1

21

5

Cell Biology

1

1

414

Maria Di Bartolomeo

×

167

Publications

12K

Citations

53

H-Index

YearCitations

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang,

The Lancet

2018

1.3K

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial

Cathy Eng, Tae Won Kim, Johanna C. Bendell,

The Lancet Oncology

2019

543

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro� Doki, Jaffer A. Ajani, Ken Kato,

UCL Discovery (University College London)

2022

532

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

Sun Young Rha, Do‐Youn Oh, Patricio Yañez,

The Lancet Oncology

2023

521

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

Federica Perrone, Andrea Lampis, Marta Orsenigo,

Annals of Oncology

2008

414

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Salvatore Siena, Maria Di Bartolomeo, Kanwal Raghav,

The Lancet Oncology

2021

392

Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group

Maria Di Bartolomeo, Emilio Bajetta, Roberto Buzzoni,

Cancer

1996

296

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

Kohei Shitara, Sun Young Rha, Lucjan Wyrwicz,

The Lancet Oncology

2023

294

Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors

Emilio Bajetta, Leonardo Ferrari, Antonia Martinetti,

Cancer

1999

288

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

Page 1